ClinicalTrials.gg
RecruitingNCT07351110PINPOINTUpdated Aug 10, 2026

Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.

An interventional study of patient navigation and self-collection in Diabetes, Cervical Cancer (Early Detection) and Obesity & Overweight, sponsored by University of Florida. Recruiting at 1 site in United States. Open to female participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by University of Florida · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
25 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus by University of Florida — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · University of Florida.

Planned enrollment
11th of 12
20 · median 83
Started
2026
with 1 other
No phase
5 of 15
2 open now
Registered
14th of 15
by date

Among the 15 studies in Diabetes Mellitus by University of Florida, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 14th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

3 of the 15 studies in Diabetes Mellitus by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 25 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus by University of Florida, or all of them as a file.
02

Study summary

Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer.

Read the detailed description

We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer. We will use the six steps of the Intervention Mapping approach to guide the process of testing the intervention. This project aligns with the current efforts at the University of Florida Health Cancer Institute (UFHCI) and UF Health Internal Medicine to improve cervical cancer screening rates among under-screened women. We will partner with these efforts to test the PINPOINT intervention. Project CONTINUITY (Connecting You to Care in the Community) at UFHCI, Office of Community Outreach and Engagement (COE), is working to increase adherence to cervical screening and follow-up by; (1) providing personalized approaches to improve adherence through the combined use of patient choice for the initial screening method, community clinical navigators (CCN) and community health workers (CHWs), customized messages and support for patient portal access for test results, and (2) implementing strategies to address non-medical drivers that may influence an individual's ability to adhere to the screening, with an initial focus on removing transportation barriers through the use of a mobile outreach clinic (MOC).

Currently, a patient navigator supervised by Dr. Dianne Goede identifies patients who have an upcoming office visit and are due for cervical cancer screening at UF Health Internal Medicine. The patient navigator outreaches the patient, reminds them of their overdue status for cervical cancer screening and the importance of cervical cancer screening, and inquires if they are agreeable to complete screening at the scheduled office visit. We will reach out to patients who remain unscreened for cervical cancer 2 months after their scheduled visit with UF Health Internal Medicine. We will obtain a list of patients from the UF Health Consent2Share database. Patients who agree to participate in our study will be randomized to either receive the PINPOINT intervention (self-collection test with patient navigation) or standard of care (reminder to screen from UF Health Internal Medicine). We will use the sealed envelope randomization method to assign participants to either treatment or control groups right after intake.

We will pilot the PINPOINT intervention at UF Internal Medicine clinics and use Proctor's Framework for Implementation Outcomes to evaluate the intervention. Changes will be made to the intervention protocol and tested in a future randomized trial with a larger sample. Hypothesis: PINPOINT will meet the needs of women living with socioeconomic challenges, T2D, and obesity, and will align with the clinical workflow. PINPOINT will be appropriate, feasible and acceptable.27 Outcome: The PINPOINT intervention will have positive outcomes in terms of feasibility and acceptability among patients.

03

Conditions studied

  • Diabetes
  • Cervical Cancer (Early Detection)
  • Obesity & Overweight

Keywords

  • cervical cancer screening
  • self-collection
  • self-sampling
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following eligibility criteria will be used to determine inclusion into the study:

  1. Using the American Cancer Society (ACS) screening recommendations, adults aged over the age of 25 will be eligible
  2. Active UF Internal Medicine patient and has had an appointment in the last 2 months.
  3. Assigned sex at birth is female
  4. Have Obesity or Type 2 Diabetes
  5. Not currently pregnant (self-report)
  6. Have not given birth in the prior 12 weeks
  7. No previous history of cervical cancer
  8. No previous history of a hysterectomy
  9. Have not undergone cancer screening in the past 3 years or more
  10. Reside in the UFHCI Catchment Area (Alachua, Baker, Bradford, Citrus, Clay, Columbia, Dixie, Gadsden, Gilchrist, Hamilton, Jefferson, Lafayette, Lake, Leon, Levy, Madison, Marion, Putnam, Sumter, Suwannee, Taylor, UnioF1n, or Wakulla County).
  11. Have a mobile phone or access to a mobile phone that can be used to receive messages, or a valid email address.
  12. Are not currently scheduled to receive cervical cancer screening via clinician sampling (pap smear).

Exclusion criteria

Exclusion Criteria:

  • Previous history of cervical cancer
  • Total hysterectomy
  • Pregnant
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Intervention

    PINPOINT intervention arm will entail assigning patients to a patient navigator to assist them with screening reminders and address any barriers they have to screening, education on cervical cancer screening, and patients will also be offered the opportunity to self-collect their sample for cervical cancer screening.

    Behavioral: patient navigation and self-collection

  • No intervention
    Control Arm

    No intervention arm, patients will receive reminders for screening according to current clinical practice

Interventions

  • Behavioralpatient navigation and self-collection

    Patients will receive a combination of patient navigation, education, and cervical cancer self-collection sampling as part of the intervention to support cervical cancer screening.

    Also known as: self-collection, self-sampling, patient navigation

06

What researchers measure

Primary outcomes

  1. Cervical cancer screening

    receiving cervical cancer screening either via self-collection, pap smear, or hpv testing

    Time frame: within 6 months

Secondary outcomes

  1. Acceptability

    How agreeable or satisfactory participants find the intervention or implementation strategy. Questions include, HPV Self-Collection meets my approval, HPV Self-Collection is appealing to me, I like HPV Self-Collection, and I welcome HPV Self-Collection. Participants will fill a 4 point likert scale for each, (completely disagree, disagree, neither agree not disagree, agree, completely agree).

    Time frame: from enrollment until they complete screening or at the end of the trial at 6 months

  2. Appropriateness

    The perceived fit or compatibility of the intervention for a specific setting, provider, or consumer, or to address a problem. Questions include, HPV Self-Collection seems fitting, HPV Self-Collection seems suitable, HPV Self-Collection seems applicable., and HPV Self-Collection seems like a good match. Participants will fill a 4 point likert scale for each, (completely disagree, disagree, neither agree not disagree, agree, completely agree).

    Time frame: from enrollment until they complete screening or at the end of the trial at 6 months

  3. Feasibility measure

    \- The extent to which an intervention can be successfully used in a given setting. Questions include, HPV Self-Collection seems implementable, HPV Self-Collection seems possible, HPV Self-Collection seems doable, and HPV Self-Collection seems easy to use. Participants will fill a 4 point likert scale for each, (completely disagree, disagree, neither agree not disagree, agree, completely agree).

    Time frame: from enrollment until they complete screening or at the end of the trial at 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mkuu RS, Staras SA, Szurek SM, D'Ingeo D, Gerend MA, Goede DL, Shenkman EA. Clinicians' perceptions of barriers to cervical cancer screening for women living with behavioral health conditions: a focus group study. BMC Cancer. 2022 Mar 9;22(1):252. doi: 10.1186/s12885-022-09350-5. PubMed 35264120 ↗
  • Mkuu RS, Tohme S, Rivero-Mendoza D, Salloum RG, Goede D, Bruggeman B, Nicholson K, Hall JM, Bylund C, Woodard JN, Hensley J, Shenkman EA, Donahoo WT, Mulugeta A, Hernandez M, Staras SA. Improving Patient Education Materials for HPV Self-Collection: Insights from Women at High Risk of Developing Cervical Cancer. Cancer Manag Res. 2025 Dec 24;17:3273-3284. doi: 10.2147/CMAR.S552282. eCollection 2025. PubMed 41467104 ↗
  • Mkuu RS, Staras SA, Chakrabarti C, Hall J, Harvey I, Salloum RG, Barrow S, Ortega S, Woodard J, Seals K, Rawls A, Meduri Y, Donahoo WT, Goede DL, Shenkman EA. Acceptability of HPV self-collection: A qualitative study of Black women living with type II diabetes and social vulnerability. J Clin Transl Endocrinol. 2024 Feb 25;35:100331. doi: 10.1016/j.jcte.2024.100331. eCollection 2024 Mar. PubMed 38444842 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Deidentified data will be available after the results of the study are published.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 20, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351110
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Rahma Mkuu, PhD
Contact
rmkuu@ufl.edu
(352) 294-8419
Daniela Rivero-Mendoza, MS.
Contact
crivero@ufl.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion